Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CTSE | P14091 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931861 | 1.00 | BACE1 (0.53) | BACE1KCNH2CYP3A4CTSECYP2C19 | |
| SCHEMBL932399 | 1.00 | BACE1 (0.53) | BACE1KCNH2CYP3A4CTSECYP2C19 | |
| SCHEMBL932679 | 0.76 | BACE1 (0.41) | BACE1KCNH2CYP3A4CTSECYP2C19 | |
| SCHEMBL932626 | 0.74 | BACE1 (0.65) | BACE1KCNH2BACE2 | |
| SCHEMBL931601 | 0.73 | BACE1 (0.50) | BACE1KCNH2BACE2 | |
| SCHEMBL931425 | 0.72 | BACE1 (0.52) | BACE1KCNH2BACE2 | |
| SCHEMBL931135 | 0.72 | BACE1 (0.52) | BACE1KCNH2BACE2 | |
| SCHEMBL931281 | 0.69 | BACE1 (0.60) | BACE1KCNH2BACE2 | |
| SCHEMBL931835 | 0.69 | BACE1 (1.00) | BACE1KCNH2CTSEBACE2 | |
| SCHEMBL945139 | 0.68 | BACE1 (0.42) | BACE1CYP3A4CTSECYP2C19SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | claimed |
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |